Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf A.; Mäurer, Mathias; Aktaş, Orhan; Baum, K.; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czapliński, Adam; Deisenhammer, Florian; Pauli, Franziska Di; Pasquier, Renaud Du; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; Goebels, Norbert; Guger, Michael; Haghikia, Aiden; Hartung, Hans‐Peter; Heidenreich, Fedor; Hoffmann, Olaf; Kallmann, Boris; Kleinschnitz, Christoph; Klotz, Luisa; Leussink, Verena I.; Leutmezer, Fritz; Limmroth, Volker; Lünemann, Jan D.; Lutterotti, Andreas; Meuth, Sven G.; Meyding‐Lamadé, Uta; Platten, Michael; Rieckmann, Peter; Schmidt, Stephan; Tumani, Hayrettin; Weber, Frank; Weber, Martin; Zettl, Uwe K.; Ziemssen, Tjalf; Zipp, Frauke

doi:10.1177/17562864211039648

Cited by 107 publications

(120 citation statements)

References 137 publications

(256 reference statements)

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…MS is a complex, most likely autoimmune-mediated inflammatory neurodegenerative disease of the central nervous system (CNS). In Germany, an estimated 200,000 people suffered from such disease in 2014 [ 67 ], and this number increased to 250,000 in 2021 [ 68 ].…”

Section: New Halogen-containing Drugsmentioning

confidence: 99%

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use

et al. 2022

View full text Add to dashboard Cite

This review describes the recent Food and Drug Administration (FDA)-approved drugs (in the year 2021) containing at least one halogen atom (covalently bound). The structures proposed throughout this work are grouped according to their therapeutical use. Their synthesis is presented as well. The number of halogenated molecules that are reaching the market is regularly preserved, and 14 of the 50 molecules approved by the FDA in the last year contain halogens. This underlines the emergent role of halogens and, in particular, of fluorine and chlorine in the preparation of drugs for the treatment of several diseases such as viral infections, several types of cancer, cardiovascular disease, multiple sclerosis, migraine and inflammatory diseases such as vasculitis.

show abstract

Section: New Halogen-containing Drugsmentioning

confidence: 99%

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Disease-modifying drugs (DMDs) for MS are immunosuppressive or immunomodulatory [ 12 , 13 , 14 ]. While there are several DMDs available to treat patients with RRMS and SPMS [ 15 , 16 ], there is currently only one drug approved for patients with PPMS (ocrelizumab) [ 17 ]. Aside from DMDs, MS patients mostly require symptomatic drugs as well as medication for comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy

et al. 2022

View full text Add to dashboard Cite

Polypharmacy (PP) is a common problem in modern medicine, especially known to affect patients with chronic diseases such as multiple sclerosis (MS). With an increasing number of drugs taken, the risk of potential drug–drug interactions (pDDIs) is rising. This study aims to assess the prevalence and clinical relevance of polypharmacy and pDDIs in patients with MS. Pharmacological data of 627 patients with MS were entered into two drug–drug-interaction databases to determine the number and severity of pDDIs for each patient. The patients were divided into those with and without PP (total PP and prescription medication PP [Rx PP]). Of the 627 patients included, 53.3% and 38.6% had total PP and Rx PP, respectively. On average, every patient took 5.3 drugs. Of all patients, 63.8% had at least one pDDI with a mean of 4.6 pDDIs per patient. Less than 4% of all pDDIs were moderately severe or severe. Medication schedules should be checked for inappropriate medication and for possible interacting drugs to prevent pDDIs. Physicians as well as pharmacists should be more sensitive towards the relevance of pDDIs and know how they can be detected and avoided.

show abstract

“…Furthermore, the results of He et al 9 highlight that an early switch is a relevant scenario in clinical practice. Although supported by the Multiple Sclerosis Therapy Consensus Group, 29 an immediate use of highly effective DMTs is still linked to a highly active disease course and poor prognosis in current treatment recommendations. 5 , 6 For example, the German S2k guideline, which had been revised in May 2021, recommends a switch strategy to highly effective DMTs including anti-CD20 antibodies after initial standard treatment.…”

Section: Discussionmentioning

confidence: 99%

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

Koeditz¹,

Frensch²,

Bierbaum

et al. 2022

Multiple Sclerosis Journal - Experimental, Translational and Cl

Self Cite

View full text Add to dashboard Cite

Background Evidence suggests that early highly efficacious therapy in relapsing multiple sclerosis is superior to escalation strategies. Objective A cost-consequence analysis simulated different treatment scenarios with ofatumumab (OMB), dimethyl fumarate (DMF) and glatiramer acetate (GA): immediate OMB initiation as first treatment, early switch to OMB after 1 year on DMF/GA, late switch after 5 years or no switch. Methods An EDSS-based Markov model with a 10-year time horizon was applied. Cycle transitions included EDSS progression, improvement or stabilization, treatment discontinuation, relapse or death. Input data were extracted from OMB trials, a network meta-analysis, published literature, and publicly available sources. Results The late switch compared to the immediate OMB scenario resulted in a lower proportion of patients with EDSS 0–3 (Δ − 7.5% DMF; Δ − 10.3% GA), more relapses (Δ + 0.72 DMF; Δ + 1.23 GA) and lower employment rates (Δ − 4.0% DMF; Δ − 5.6% GA). The same applies to late versus early switches. No switch scenarios resulted in worse outcomes. Higher drug acquisition costs in the immediate OMB and early switch scenarios were almost compensated by lower costs for patient care and productivity loss. Conclusion Immediate OMB treatment and an early switch improves clinical and productivity outcomes while remaining almost cost neutral compared to late or no switches.

show abstract

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Cited by 107 publications

References 137 publications

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use

Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

Contact Info

Product

Resources

About